PMID- 38417828
OWN - NLM
STAT- MEDLINE
DCOM- 20240301
LR  - 20240327
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 39
IP  - 1
DP  - 2024 Feb
TI  - Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 
      Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
PG  - 109-126
LID - 10.3803/EnM.2023.1839 [doi]
AB  - BACKGRUOUND: No recent meta-analysis has holistically analyzed and summarized the 
      efficacy and safety of omarigliptin in type 2 diabetes mellitus (T2DM). We 
      conducted a meta-analysis to address this knowledge gap. METHODS: Electronic 
      databases were searched to identify randomized controlled trials (RCTs) that 
      included patients with T2DM who received omarigliptin in the intervention arm. 
      The control arm consisted of either a placebo (passive control group [PCG]) or an 
      active comparator (active control group [ACG]). The primary outcome assessed was 
      changes in hemoglobin A1c (HbA1c), while secondary outcomes included variations 
      in glucose levels, achievement of glycemic targets, adverse events (AEs), and 
      hypoglycemic events. RESULTS: From 332 initially screened articles, data from 16 
      RCTs involving 8,804 subjects were analyzed. Omarigliptin demonstrated 
      superiority over placebo in reducing HbA1c levels (mean difference, -0.58%; 95% 
      confidence interval, -0.75 to -0.40; P<0.00001; I2=91%). Additionally, 
      omarigliptin outperformed placebo in lowering fasting plasma glucose, 2-hour 
      postprandial glucose, and in the percentage of participants achieving HbA1c 
      levels below 7.0% and 6.5%. The glycemic efficacy of omarigliptin was similar to 
      that of the ACG across all measures. Although the omarigliptin group experienced 
      a higher incidence of hypoglycemic events compared to the PCG, the overall AEs, 
      serious AEs, hypoglycemia, and severe hypoglycemia were comparable between the 
      omarigliptin and control groups (PCG and ACG). CONCLUSION: Omarigliptin has a 
      favorable glycemic efficacy and safety profile for managing T2DM.
FAU - Kamrul-Hasan, A B M
AU  - Kamrul-Hasan ABM
AD  - Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
FAU - Alam, Muhammad Shah
AU  - Alam MS
AD  - Department of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh.
FAU - Talukder, Samir Kumar
AU  - Talukder SK
AD  - Department of Endocrinology, Rangpur Medical College, Rangpur, Bangladesh.
FAU - Dutta, Deep
AU  - Dutta D
AD  - Department of Endocrinology, Center for Endocrinology, Diabetes, Arthritis and 
      Rheumatism (CEDAR) Superspeciality Healthcare, New Delhi, India.
FAU - Selim, Shahjada
AU  - Selim S
AD  - Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 
      Bangladesh.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20240123
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 
      (2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
RN  - 0 (Heterocyclic Compounds, 2-Ring)
RN  - 0 (Pyrans)
SB  - IM
MH  - Humans
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Glycated Hemoglobin
MH  - Blood Glucose/analysis
MH  - Hypoglycemic Agents/adverse effects
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Hypoglycemia/chemically induced/epidemiology
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use
MH  - *Heterocyclic Compounds, 2-Ring
MH  - *Pyrans
PMC - PMC10901664
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Glycated hemoglobin
OT  - Hypoglycemia
OT  - Meta-analysis
OT  - Omarigliptin
OT  - Safety
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2024/02/29 00:42
MHDA- 2024/03/01 06:45
PMCR- 2024/02/01
CRDT- 2024/02/28 19:57
PHST- 2023/10/06 00:00 [received]
PHST- 2023/11/30 00:00 [accepted]
PHST- 2024/03/01 06:45 [medline]
PHST- 2024/02/29 00:42 [pubmed]
PHST- 2024/02/28 19:57 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - EnM.2023.1839 [pii]
AID - enm-2023-1839 [pii]
AID - 10.3803/EnM.2023.1839 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2024 Feb;39(1):109-126. doi: 10.3803/EnM.2023.1839. 
      Epub 2024 Jan 23.